On this page
Overview
Product & regulatory status
EGRIFTA SV has a US-approved indication. This does not confer approval on every tesamorelin preparation or on general weight-loss use.
How it acts
Tesamorelin stimulates growth-hormone-releasing factor receptors and increases GH and IGF-1. This explains why hormone and glucose monitoring are relevant; it does not turn it into a general fat-loss recommendation. [1]
What the evidence shows
Approved use and limits
EGRIFTA SV is indicated for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight-loss management. [1]
What the pivotal studies followed
The label reports studies in adults with HIV-associated abdominal fat accumulation, using abdominal fat measures rather than general weight loss as the main clinical question. The evidence should remain attached to that population and indication. [1]
What remains unknown
Long-term cardiovascular safety has not been established. Benefits for unrelated wellness goals should not be inferred.
Safety
Discuss medical history and medicines
The label includes contraindications involving active malignancy, pregnancy, and disruption of the hypothalamic-pituitary axis. Warnings include elevated IGF-1, fluid retention, and glucose intolerance. It also describes drug interactions. [1]
EGRIFTA SV has specific handling instructions
The SV label distinguishes its formulation from other tesamorelin products. It calls for immediate use after mixing and says not to refrigerate or freeze the mixed solution. Read the exact product’s current instructions; a generic peptide storage rule can be wrong. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [2]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [3]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Are all tesamorelin products interchangeable?
No. The linked label applies to EGRIFTA SV. Confirm the exact product and its instructions with your prescriber or pharmacist.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- EGRIFTA SV (tesamorelin) prescribing information2024 revision · US product label · indication, warnings, interactions
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.